Discover 1,705 paid clinical trials in Detroit, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,705
Active & Responsive
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
for
Ulcerative Colitis
Location: Clinton Township MI, Hamilton, Dayton OH, Mississauga,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18 - 70+
Code: NCT07186101
Phase2, Recruiting
Active & Responsive
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
for
Sjögren´s Disease
Location: Saint Clair Shores MI, Willowbrook IL, Charlotte NC,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07621809
Phase3, Recruiting
Active & Responsive
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
for
Primary Sjogren's Disease
Location: Saint Clair Shores MI, Chicago IL, Willowbrook IL,
Sponsor: Vor Biopharma
Sex: All
Age: 18 - 70+
Code: NCT07404865
Phase3, Recruiting
Active & Responsive
VTP-1000 in Adults With Celiac Disease
for
Celiac Disease
Location: Clinton Township MI, Wyoming MI, Columbus OH,
Sponsor: Barinthus Biotherapeutics
Sex: All
Age: 18 - 70
Code: NCT06310291
Early_phase1, Recruiting
Active & Responsive
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
for
Autosomal Dominant Polycystic Kidney Disease
Location: Shelby MI, Ann Arbor MI, Chicago IL, Bethlehem PA,
Sponsor: Calico Life Sciences LLC
Sex: All
Age: 18 - 55
Code: NCT06902558
Phase2, Recruiting
Active & Responsive
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Sex: All
Age: 55 - 70+
Code: NCT06585787
Phase3, Recruiting
Active & Responsive
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention